Clinical Study
Baseline Serum Cholesterol Is Associated with a Response to Pegylated Interferon Alfa-2b and Ribavirin Therapy for Chronic Hepatitis C Genotype 2
Table 1
Characteristics of 100 studied patients with HCV genotype 2.
| | All | 100 | | | Age | 57.0 | (24–76) | | Sex (%) | | | | Male | 54 | (54) | | Female | 46 | (46) | | Height (cm) | 162 | (138–186) | | Weight (kg) | 58 | (37–87) | | BMI (kg/m2) | 22.7 | (18.4–30.8) | | Clinical finding (%) | | | | Chronic hepatitis | 93 | (93) | | Cirrhosis | 7 | (7) | | WBC (/L) | 5100 | (2100–9730) | | Hemoglobin (g/dL) | 14.0 | (10–16) | | Platelet (104/L) | 20.4 | (6.9–26.5) | | AST (IU/L) | 42 | (17–157) | | ALT (IU/L) | 52 | (11–280) | | TC (mg/dL) | 177 | (106–269) | | 177 mg/dL (%) | 50 | (50) | | 177 mg/dL (%) | 50 | (50) | | TG (mg/dL) | 88 | (56–262) | | 88 mg/dL (%) | 50 | (50) | | 88mg/dL (%) | 50 | (50) | | LDL-C (mg/dL) | 98 | (30–167) | | 98 mg/dL (%) | 50 | (50) | | 98 mg/dL (%) | 50 | (50) | | HCV RNA (KIU/mL) | 1000 | (20–40900) | | Distribution of stage of fibrosis (%) | | | | 0-1 | 43 | (43) | | 2 | 17 | (17) | | 3 | 11 | (11) | | 4 | 4 | (4) | | Unknown | 25 | (25) | | Distribution of grade of inflammation (%) | | | | 0-1 | 39 | (39) | | 2 | 34 | (34) | | 3 | 2 | (2) | | Unknown | 25 | (25) | | Treatment period (week) (%) | | | | 24 | 10 | (10) | | 24 | 83 | (83) | | 25–48 | 5 | (5) | | 48 | 2 | (2) | | Therapeutic efficacy (%) | | | | SVR | 74 | (74) | | Non-SVR | 26 | (26) |
|
|
Data are median (range) or frequency (%).
|
